Paper Details

  1. Home
  2. Paper Details

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis.

Author: ChenXiu, KouLiqiu, LiJun, LiYaling, WenQinglian, XieXiaolu

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This meta-analysis analyzed the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients. Olaparib 200-600 mg/day (excluding olaparib plus cediranib regimen) may be the most suitable PARP inhibitor for cancer patients with a high risk of hypertension. Niraparib, olaparib 800 mg/day, and olaparib combined with cediranib may increase the risk of developing hypertension in cancer patients.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians. METHODS: We used R software to conduct a meta-analysis of phase II/III randomized controlled trials (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887889/

データ提供：米国国立医学図書館（NLM）

Hypertension: A Potential Side Effect of PARP Inhibitors in Cancer Treatment

PARP inhibitors are a relatively new class of drugs used to treat certain cancers. While they have shown promise in combating tumors, this study explores a potential side effect – hypertension, or high blood pressure. Understanding this side effect is crucial for optimizing treatment and ensuring patient safety.

PARP Inhibitors: A Complex Landscape

The study analyzed data from 32 randomized controlled trials involving PARP inhibitors in cancer treatment. It found that PARP inhibitors, particularly those with higher doses or specific combinations, were associated with an increased risk of hypertension. This is an important finding because it emphasizes the need to monitor blood pressure carefully in patients receiving PARP inhibitor therapy. The study’s findings highlight the complexity of cancer treatment, where seemingly promising therapies can also have unforeseen side effects.

Managing the Risks of PARP Inhibitors

This research provides valuable information for clinicians treating cancer patients with PARP inhibitors. It underscores the need to carefully monitor blood pressure and manage hypertension effectively to prevent potential complications. It’s like navigating a desert landscape, where knowing the terrain and preparing for challenges is essential for survival. This research highlights the importance of ongoing vigilance and careful management in cancer treatment.

Dr.Camel's Conclusion

This meta-analysis provides valuable insights into the potential risk of hypertension associated with PARP inhibitors in cancer treatment. The study emphasizes the need for careful blood pressure monitoring in patients receiving these therapies. This research highlights the importance of weighing the benefits and risks of cancer treatments, just like a camel carefully assesses the terrain before embarking on a journey through the desert.

Date :
  1. Date Completed 2023-02-02
  2. Date Revised 2023-02-02
Further Info :

Pubmed ID

36717798

DOI: Digital Object Identifier

PMC9887889

Related Literature

Article Analysis
・Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.